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OBJECTIVES In this study, we evaluated the effect of S 18886, a specific thromboxane A2 receptor
antagonist, on endothelial function in patients with coronary artery disease (CAD).
BACKGROUND Impaired release of endothelial vasodilator substances and increased release of vasoconstrictor
prostanoids both contribute to endothelial dysfunction in atherosclerosis. One unresolved
question is whether vasoconstrictor prostanoids are still produced and affect vascular tone or
alter endothelium-dependent vasodilation in patients treated with aspirin.
METHODS Twenty patients with stable CAD treated with 100 mg/day aspirin were evaluated in a
randomized, double-blinded, placebo-controlled study. Twelve patients received a single oral
dose of 10 mg S 18886, and eight patients received placebo. Before and 60 min after a single
oral dose of S 18886 or placebo, flow-mediated vasodilation (FMD) was evaluated using an
echo-tracking device. Venous occlusion plethysmography was used to evaluate the effects on
forearm blood flow (FBF) of a brachial artery infusion of acetylcholine (ACh), sodium
nitroprusside (SNP), or norepinephrine before and after treatment.
RESULTS Baseline FBF was not affected by S 18886 or placebo. The vasodilator response to ACh was
significantly potentiated by S 18886 as compared with placebo (p  0.03 by analysis of
co-variance), whereas the effects of norepinephrine and SNP were unchanged. Flow-
mediated dilation increased from 2.50  1.14% to 3.84  1.80% (p  0.01) after S 18886,
but was unchanged after placebo.
CONCLUSIONS Single administration of S 18886 improved FMD and ACh-induced vasodilation in
aspirin-treated patients with CAD. These results suggest that release of endogenous agonists
of TP receptors may contribute to endothelial dysfunction, despite aspirin treatment, in
patients with atherosclerosis. (J Am Coll Cardiol 2003;41:1198–204) © 2003 by the
American College of Cardiology Foundation
Impaired endothelium-dependent relaxation is a major
characteristic of the diseased vessel wall (1,2). Endothelial
dysfunction stems chiefly from an inability of the endothe-
lial cell to release vasodilating substances such as nitric
oxide, prostacyclin, or endothelium-derived hyperpolarizing
factor (3). A current hypothesis is that impairment of
endothelium-dependent relaxation in atherosclerosis may be
paralleled by a propensity to release endothelium-
contracting factors, such as thromboxane A2 (TXA2), su-
peroxide anions, and the peptide endothelin (4).
One consequence of endothelial dysfunction is enhance-
ment of platelet-endothelial cell interactions responsible for
increased production of TXA2. Thromboxane A2 promotes
aggregation, vasoconstriction, and proliferation by docking
with a membrane-bound receptor, the TP receptor. The TP
receptors can bind to other vasoconstrictor prostanoids, such
as prostaglandin F2 (PGF2) and the PGF2-like com-
pounds isoprostanes (5). Isoprostanes are nonenzymatic
products from cell membrane phospholipids and are re-
leased in response to oxidative stress (6) in disease states
such as hypercholesterolemia (7,8), diabetes mellitus (9),
and unstable angina (10). Aspirin, which is effective in
reducing the risk of stroke and myocardial infarction, does
not inhibit isoprostane formation. Moreover, TXA2 forma-
tion may be only partly inhibited by aspirin under certain
pathologic conditions. Thus, an important question is
whether vasoconstrictor prostanoids still contribute to en-
dothelial dysfunction and affect vascular tone, even in
patients treated with aspirin.
Because a TP-receptor antagonist may inhibit the effects
of both TXA2 and isoprostanes, we designed the present
study to investigate whether S 18886, a selective TP-
receptor antagonist (11,12), could affect vascular tone
and/or improve endothelial function in patients receiving
low-dose aspirin to treat coronary artery disease (CAD).
We used a double-blinded, randomized, parallel, placebo-
controlled design to assess the effect of a single oral dose of
S 18886 on forearm blood flow (FBF) variations in 20 CAD
patients taking 100 mg/day aspirin. Endothelium-
dependent vasodilation was examined by recording brachial
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artery diameter variations in response to hyperemia and by
using venous occlusion plethysmography (VOP) to measure
the FBF response to a brachial artery infusion of acetylcho-
line (ACh).
METHODS
Patient population. We assessed endothelial function in
20 male patients with a mean (SD) age of 59  7 years
(range 49 to 69). All had stable CAD documented by a
previous coronary angiogram, with30% stenosis in at least
one site on a major branch; endothelial dysfunction mani-
festing as impaired flow-mediated dilation (FMD 4.1%)
(13,14); and a bleeding time12 min. None of the patients
had a history of a recent myocardial infarction, heart failure,
cardiac arrhythmias, or uncontrolled hypertension. Patients
with a history of hemostatic disorder, allergy, diabetes, or
heavy smoking (10 cigarettes/day) were not included in
the study. Vasodilators and antihypertensive drugs were
withdrawn at least 48 h before inclusion (except for beta-
blockers, which were maintained throughout the study
period for ethical reasons). No patients had taken any
anti-inflammatory drugs other than aspirin for at least 10
days prior to inclusion. All patients gave their written,
informed consent, and the study was approved by our
institutional Review Committee.
Study protocol. This was a double-blinded, randomized,
placebo-controlled trial. All patients received aspirin 100
mg/day for at least 10 days prior to inclusion. Preliminary
studies that we performed in other patients showed that this
aspirin dosage completely abolished arachidonic acid–
induced platelet aggregation (unpublished observations).
Patients were randomly assigned to a single 10-mg oral dose
of either S 18886 (n  12) or placebo (n  8). S 18886 and
placebo caps were provided by I.R.I.S. (Courbevoie,
France). Vascular tone and endothelium-dependent vasodi-
lation were evaluated in the forearm vascular bed before and
60 min after the S 18886 or placebo dose. Flow-mediated
vasodilation of the brachial artery was measured during a
hyperemia test using a high-resolution ultrasound echo-
tracking system to record changes in brachial artery diam-
eter (15). Then a catheter was inserted into the brachial
artery, and FBF was recorded using VOP under baseline
conditions and during subsequent brachial artery infusions
of ACh, sodium nitroprusside (SNP), and norepinephrine.
The FBF determinations by VOP were repeated 60 min
after the S 18886 or placebo dose. The brachial artery
catheter was removed, and FMD was measured in the
contralateral brachial artery.
Evaluation of FMD. The FMD measurements were per-
formed as previously described (14). All measurements were
performed after a 30-min rest in bed, in a temperature-
controlled room (22°C), with continuous blood pressure
monitoring (Finapres 2300, Ohmeda, Englewood, Colo-
rado). A high-resolution ultrasound Wall Track system (Pie
Medical, Maastricht, the Netherlands) with a 7-MHz linear
probe was used to measure the systolic and diastolic internal
diameters of the distal brachial artery. This echo-tracking
system, which analyzes radiofrequency signals, has a preci-
sion for diastolic diameter measurements of 30 m. The
FMD was measured following the increase in the brachial
artery diastolic diameter after 3 min of ischemia of the
ipsilateral hand, induced using a wrist cuff inflated at 200
mm Hg (hyperemia test). When the wrist cuff is deflated,
blood flow and shear stress increase briefly, inducing endo-
thelial nitric oxide release and FMD. The maximum diam-
eter (DM) was defined as the greatest diastolic diameter
following deflation of the cuff; measurements were made at
deflation over five or six cardiac cycles and every 30 s
thereafter for 5 min. The measurement at deflation was the
minimum diameter (DB, for basal diameter). The FMD (%)
was calculated as: 100  (DM  DB)/DB.
Measurement of FBF by VOP. The VOP measurements
were performed as previously described (15). Briefly, a
mercury-in-silastic strain gauge was placed around the
forearm. The strain gauge was electrically coupled to a
calibrated plethysmograph (Perivein, JSI, ETNA, Noisy Le
Grand, France). For each measurement, venous flow was
occluded just proximal to the elbow by rapidly inflating a
blood pressure cuff to 40 mm Hg. A wrist cuff was inflated
to suprasystolic pressures starting 1 min before each mea-
surement to exclude the hand circulation from blood flow
determination. The FBF measurements are reported in
ml/min per 100 ml of forearm volume, and each value is the
mean value of at least three determinations. Systolic blood
pressure, diastolic blood pressure, mean blood pressure, and
heart rate were monitored continuously (Finapres 2300,
Ohmeda). All studies were performed in the morning, in a
quiet room kept at a controlled temperature of 22°C. While
the subject was in the supine position, a catheter was
inserted after local anesthesia (2% xylocaine) into the
brachial artery of the nondominant arm, which was elevated
to a level slightly above the right atrium. To establish rest
control FBF values, 5% dextrose in water was administered
for 30 min, and blood flow measurements were then
repeated until a stable baseline condition was obtained.
Infusion of vasoactive agents was then started. Between each
series of drug injections, FBF was allowed to return to its
basal value. During this period, 5% dextrose in water was
infused. Three drugs were used to explore endothelial
function: 1) ACh (Pharmacie Centrale des Hoˆpitaux, Paris,
Abbreviations and Acronyms
ACh  acetylcholine
AUC  area under the curve
CAD  coronary artery disease
FBF  forearm blood flow
FMD  flow-mediated dilation
PGF2  prostaglandin F2
SNP  sodium nitroprusside
TXA2  thromboxane A2
VOP  venous occlusion plethysmography
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France), as a continuous infusion at rates of 20, 40, and 80
g/min; 2) SNP (Nitriate, Laboratoires SERB, Paris,
France), at rates of 0.5 and 1 g/min; and 3) norepinephrine
(Pharmacie Centrale des Hoˆpitaux) at rates of 100, 500, and
1000 pmol/min.
Safety measures. Bleeding-time measurements were ob-
tained at selection and 2 h after treatment with either S
18886 or placebo. Bleeding-time measurements were per-
formed according to the Ivy Nelson method, on the fore-
arm, with a Simplate device (Organon Technika, Eppel-
heim, Germany) (16). Physical examinations, cardiovascular
parameters (supine blood pressure, heart rate, and electro-
cardiography), blood and urine biochemical parameters,
hematology, and coagulation tests were conducted through-
out the study.
Statistical analysis. All data are reported as the mean value
 SD. The results of VOP are expressed, for each patient,
as the area under the curve (AUC) of FBF for ACh, SNP,
and norepinephrine infusions (17). The AUCs of each
treatment group were compared using an analysis of co-
variance (ANCOVA) model, including the baseline values
and taking into account the unequal variances between the
treatment groups in order to improve the accuracy of the
estimations. The paired t test was used to study the change
between baseline and treatment values in each treatment
group. The type 1 error rate was set at 5%.
RESULTS
Study population. The general characteristics of the as-
sessed patients are shown in Table 1. Age, hemodynamic
parameters, and risk factors did not differ between the S
18886 and placebo groups. Most patients (90%) were
receiving beta-blocking therapy at the time of the study.
The groups did not significantly differ with respect to
previous treatment with vasodilators and hydroxymethyl
glutaryl coenzyme A reductase inhibitors. Bleeding time
measured at baseline in patients already treated with 100
mg/day aspirin was similar in the S 18886 and placebo
groups (5.45  2.5 vs. 4.9  1.5 min, respectively) and
remained unchanged after treatment (5.1  1.2 vs. 4.3 
1.3 min). No clinically relevant biochemical, hematologic,
or coagulation abnormalities or changes in cardiovascular
parameters possibly related to drug administration were
detected. No serious adverse events were reported.
Brachial artery FMD. Brachial artery diameters recorded
at baseline in the S 18886 and placebo groups were 5.48 
0.47 and 5.32  0.34 mm, respectively, during the control
phase and remained unchanged (5.24  0.56 and 5.17 
0.59 mm) after treatment. Brachial artery FMD also did not
differ at baseline between the S 18886 and placebo groups
(2.50  1.14% vs. 2.46  0.76%, respectively; p  NS).
After administration of S 18886, brachial artery FMD
increased by 50% (2.50  1.14% to 3.84  1.80%, p 
0.01), whereas it remained unchanged after placebo (2.46
0.76% to 3.01  1.30%, p  NS) (Fig. 1).
Measurements of FBF using VOP. The baseline mea-
surements did not differ between the S 18886 and placebo
groups (Fig. 2). The mean baseline FBF values were 1.9 
0.8 and 2.0  0.5 ml/min per 100 ml in the S 18886 and
placebo groups, respectively (Fig. 2). The increases in FBF
(expressed as the mean AUC arbitrary units) were 499.8 
265.2 and 482.0  259.6 with ACh and 3.78  1.16 and
4.10  0.69 with SNP for the S 18886 and placebo groups,
respectively. The decreases in FBF with norepinephrine
were similar in the S 18886 group (1255.9  558.2) and
placebo group (1548.1  469.5).
Neither S 18886 nor placebo altered the baseline FBF
values (Fig. 2). The vasodilator response to ACh, which
significantly increased after treatment with S 18886, re-
mained unchanged after dosing with placebo. As shown in
Figure 2, the ACh-induced FBF increase in the S 18886
group (expressed as mean AUC) was larger after dosing
Table 1. Patient Characteristics
S 18886 Group
(n  12)
Placebo Group
(n  8)
p
Value
Age (yrs) 59.4  6.2 58.4  8.4 NS
Body mass index (kg/m2) 25.5  3.0 26.0  3.1 NS
Heart rate (beats/min) 59.3  6.6 54.8  5.1 NS
Systolic blood pressure
(mm Hg)
130.0  13.8 128.8  11.3 NS
Diastolic blood pressure
(mm Hg)
70.0  10.7 67.9  7.3 NS
Total cholesterol (mmol/l) 5.6  1.2 4.8  1.0 NS
LDL cholesterol (mmol/l) 3.6  1.0 2.9  1.0 NS
HDL cholesterol (mmol/l) 1.2  0.3 1.0  0.3 NS
Blood glucose (mmol/l) 5.7  0.5 6.3  1.8 NS
Treatment with* (n)
Beta-blockers 10 8 NS
HMG CoA reductase
inhibitors
9 5 NS
ACE inhibitors 1 0 NS
Calcium channel blockers 8 3 NS
*All patients were treated by aspirin 100 mg/day.
ACE angiotensin-converting enzyme; HDL high-density lipoprotein; HMG
CoA  hydroxymethyl glutaryl coenzyme A; LDL  low-density lipoprotein; NS 
not significant.
Figure 1. The flow-mediated dilation (FMD) variations in response to
hyperemia. The FMD values (expressed as the percentage of increase in
brachial artery diameter following hyperemia) are shown before and after
treatment with placebo or S 18886. p  0.01 for comparisons of
pre-treatment to post-treatment values in the S 18886 group.
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than before treatment (849.3  590.0 vs. 499.8  265.2,
respectively; p  0.02). Comparisons of values recorded
after treatment showed that the FBF response to ACh was
significantly more increased in the S 18886 group than in
the placebo group (849.3  590.0 vs. 508.7  293.9,
respectively; p  0.03 by ANCOVA). In contrast to
ACh-induced vasodilation, SNP-induced vasodilation and
norepinephrine-induced vasoconstriction were unaffected by
S 18886 treatment (ANCOVA) (Fig. 3 and 4) .
DISCUSSION
In this double-blinded, randomized, placebo-controlled
study, we showed that a single 10-mg oral dose of S 18886,
a new TP-receptor antagonist, significantly improved
endothelium-dependent vasodilation in the peripheral ar-
teries of patients with CAD treated with aspirin. There was
an improvement in both ACh- and flow-mediated vasodi-
lation. In addition, S 18886 neither affected baseline fore-
arm vascular tone nor altered FBF responses to brachial
artery infusion of SNP or norepinephrine.
Vasoconstrictor prostanoids are involved in the control
of endothelial function. Aspirin is the most widely used
prophylactic treatment for acute thrombotic complications
of atherosclerotic cardiovascular disease. Its therapeutic
effect is widely attributed to its ability to inhibit cyclooxy-
genase and, thus, the production of TXA2, which promotes
platelet aggregation, vasoconstriction, and cell proliferation.
Aspirin is usually given at low dosages that are expected to
selectively inhibit platelet TXA2 formation. However, re-
cent studies have suggested that aspirin may improve
endothelial function in atherosclerosis when infused in high
concentrations (18,19). These findings led to the hypothesis
that aspirin may inhibit not only platelet TXA2 synthesis,
but also formation of constricting factor synthesized in
response to endothelial cell stimulation.
Acetylcholine stimulation of endothelial vasoconstrictor
Figure 2. The forearm blood flow (FBF) variations in response to brachial
artery acetylcholine (ACh) infusion. Acetylcholine (20, 40, and 80 g/min)
was infused into the brachial artery, and FBF variations (expressed in
ml/min per 100 ml) were recorded using venous occlusion plethysmogra-
phy. The FBF variations are shown before and after treatment in the S
18886-treated group (top) and placebo group (bottom). Statistical analysis
was performed on the area under the curve of FBF. p  0.02 for
comparison of values before and after treatment in the S 18886 group
(paired t test); p  0.03 for comparison between values recorded after
treatment between the S 18886 and placebo groups (analysis of covariance).
Figure 3. The forearm blood flow (FBF) variations in response to brachial
artery sodium nitroprusside (SNP) infusion. Sodium nitroprusside (0.5 and
1.0 g/min) was infused into the brachial artery, and FBF variations
(expressed in ml/min per 100 ml) were recorded using venous occlusion
plethysmography. The FBF variations are shown before and after S 18886
(top) or placebo (bottom). Statistical analysis was performed on the area
under the curve of FBF. No significant differences were observed between
the post-treatment values recorded in the S 18886 and placebo groups
(analysis of covariance).
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prostanoid release has been well documented in previous
experimental studies (20,21). Prostanoids have been impli-
cated in endothelial dysfunction in hypertension (21,22),
heart failure (23,24), and atherosclerosis (18). In these
pathologic states, the defective response to ACh or shear
has been widely ascribed to an imbalance between the
release of endothelium-dependent relaxing factors and va-
soconstricting factors.
Recent studies suggest that “aspirin-insensitive” vasocon-
strictor prostanoids, such as isoprostanes, may be synthe-
sized by endothelial cells in atherosclerotic cardiovascular
diseases (10). Superoxide anion production has been shown
in response to ACh in canine basilar artery endothelial cells,
as well as shear stress in human umbilical endothelial cells
(25–27). Therefore, ACh and shear stress may potentially
lead to increased formation of isoprostanes, which are not
blocked by aspirin treatment.
TP-receptor blockade improves endothelial function. In
the present study of patients with documented CAD, we
found that TP-receptor blockade improved both ACh- and
shear stress–stimulated endothelium-dependent vasodila-
tion. Treatment with S 18886 neither altered baseline
forearm blood flow nor affected the responses to SNP or
norepinephrine infusion, suggesting that it selectively in-
creased endothelium-dependent vasodilation. Thus, our
results strongly suggest that in patients with atherosclerosis,
vasoconstrictor prostanoids acting on TP receptors are
actively produced and released in response to endothelial
stimulation by either ACh or shear stress. In keeping with
standard clinical practice, all patients were treated with
low-dose oral aspirin, which is known to inhibit platelet
TXA2 production (28). As expected, we found that arachi-
donic acid–induced platelet aggregation was abolished in
patients treated with this dose of aspirin. It is therefore
unlikely that the effect of TP-receptor blockade observed in
our patients was related to inhibition of residual platelet
TXA2 formation. However, we cannot exclude that sys-
temic endothelial or other vascular cells remain capable of
producing TXA2 through a transcellular mechanism (29)
involving a functional cyclooxygenase pathway. Other en-
dogenous TP-receptor agonists that are likely to play a role
in patients with CAD include isoprostanes, whose produc-
tion is probably increased in situations of cell dysfunction.
The observation that a higher dose of aspirin improves
endothelium-dependent vasodilation in patients with ath-
erosclerosis does not conflict with this hypothesis, given that
high concentrations of aspirin are known to exhibit antiox-
idant properties (30). Whatever the type of vasoconstrictor
prostanoids involved in these responses, our results clearly
indicate that TP-receptor blockade is more powerful than
aspirin in limiting the deleterious effects of constrictive
prostanoids in atherosclerosis. In theory, a TP-receptor
antagonist may also offer the advantage of not interfering
with the synthesis of vasodilator prostanoids. In Figure 5,
we propose a mechanism to explain the beneficial effect of S
18886 on endothelial function.
These results are also consistent with a recent report by
Cayatte et al. (31), in which S 18886 delayed atherogenesis
in apolipoprotein E–deficient knockout mice. Interestingly,
aspirin had no effect in this study, although it abolished
TXA2 formation. It could be concluded that TP-receptor
blockade inhibited atherosclerosis by a mechanism indepen-
dent of platelet-derived TXA2. Together with our results,
these findings suggest that TP-receptor blockade may offer
greater vascular protection than aspirin.
Conclusions. The present results also provide additional
support for the possibility that the impairment of
endothelium-dependent relaxation seen in patients with
atherosclerosis may be paralleled by a propensity to release
TP-receptor agonists. The precise nature of these agonists
and the mechanism involved in their production still need to
be elucidated. This may partly explain the resistance to
aspirin, which is associated with an increased risk of
Figure 4. The forearm blood flow (FBF) variations in response to brachial
artery norepinephrine (NE) infusion. Norepinephrine (100, 500, and 1,000
pmol/min) was infused into the brachial artery, and FBF variations
(expressed in ml/min per 100 ml) were recorded using venous occlusion
plethysmography. The FBF variations are shown before and after S 18886
(top) or placebo (bottom). Statistical analysis was performed on the area
under the curve of FBF. No significant differences were observed between
the post-treatment values recorded in the S 18886 and placebo groups
(analysis of covariance).
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myocardial infarction and cardiovascular death (32). This
suggests that TP antagonists may be candidates in further
trials to evaluate their potential benefits in atherosclerosis.
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